6.
De Benedetti G, Vaiano A
. Oral azithromycin and oral doxycycline for the treatment of Meibomian gland dysfunction: A 9-month comparative case series. Indian J Ophthalmol. 2019; 67(4):464-471.
PMC: 6446637.
DOI: 10.4103/ijo.IJO_1244_17.
View
7.
Park S, Perez Perez J, Perez Gandara B, Agudelo C, Ortega R, Ahmed H
. Mechanisms Linking COPD to Type 1 and 2 Diabetes Mellitus: Is There a Relationship between Diabetes and COPD?. Medicina (Kaunas). 2022; 58(8).
PMC: 9415273.
DOI: 10.3390/medicina58081030.
View
8.
Balighi K, Heidari S, Kavyani M, Kamyab Hesari K, Tootoonchi N
. Dipeptidyl-Peptidase 4 Inhibitor-Induced Variants of Bullous Pemphigoid: A Case Series of Four Patients. Case Rep Dermatol. 2022; 14(3):350-355.
PMC: 9710457.
DOI: 10.1159/000527913.
View
9.
Ozdemir M, Buyukbese M, Cetinkaya A, Ozdemir G
. Risk factors for ocular surface disorders in patients with diabetes mellitus. Diabetes Res Clin Pract. 2003; 59(3):195-9.
DOI: 10.1016/s0168-8227(02)00244-9.
View
10.
Akanuma Y, Kosaka K, Kanazawa Y, Kasuga M, Fukuda M, Aoki S
. Long-term comparison of oral hypoglycemic agents in diabetic retinopathy. Gliclazide vs. other sulfonylureas. Diabetes Res Clin Pract. 1988; 5(2):81-90.
DOI: 10.1016/s0168-8227(88)80046-9.
View
11.
Jongkhajornpong P, Anothaisintawee T, Lekhanont K, Numthavaj P, McKay G, Attia J
. Short-term Efficacy and Safety of Biological Tear Substitutes and Topical Secretagogues for Dry Eye Disease: A Systematic Review and Network Meta-analysis. Cornea. 2021; 41(9):1137-1149.
PMC: 9365259.
DOI: 10.1097/ICO.0000000000002943.
View
12.
Mangoli M, Bubanale S, Bhagyajyothi B, Goyal D
. Dry eye disease in diabetics versus non-diabetics: Associating dry eye severity with diabetic retinopathy and corneal nerve sensitivity. Indian J Ophthalmol. 2023; 71(4):1533-1537.
PMC: 10276718.
DOI: 10.4103/IJO.IJO_2680_22.
View
13.
Park C, Lee H, Kim M, Kim E, Kim J, Kim T
. Comparison of 0.05% cyclosporine and 3% diquafosol solution for dry eye patients: a randomized, blinded, multicenter clinical trial. BMC Ophthalmol. 2019; 19(1):131.
PMC: 6580465.
DOI: 10.1186/s12886-019-1136-8.
View
14.
Donthineni P, Kammari P, Shanbhag S, Singh V, Das A, Basu S
. Incidence, demographics, types and risk factors of dry eye disease in India: Electronic medical records driven big data analytics report I. Ocul Surf. 2019; 17(2):250-256.
DOI: 10.1016/j.jtos.2019.02.007.
View
15.
De Freitas G, Ferraz G, Gehlen M, Skare T
. Dry eyes in patients with diabetes mellitus. Prim Care Diabetes. 2020; 15(1):184-186.
DOI: 10.1016/j.pcd.2020.01.011.
View
16.
Supiyaphun C, Jongkhajornpong P, Rattanasiri S, Lekhanont K
. Prevalence and risk factors of dry eye disease among University Students in Bangkok, Thailand. PLoS One. 2021; 16(10):e0258217.
PMC: 8486107.
DOI: 10.1371/journal.pone.0258217.
View
17.
Phan K, Smith S
. Topical corticosteroids and risk of diabetes mellitus: systematic review and meta-analysis. J Dermatolog Treat. 2019; 32(3):345-349.
DOI: 10.1080/09546634.2019.1657224.
View
18.
Haber S, Benson V, Buckway C, Gonzales J, Romanet D, Scholes B
. Lifitegrast: a novel drug for patients with dry eye disease. Ther Adv Ophthalmol. 2019; 11:2515841419870366.
PMC: 6710705.
DOI: 10.1177/2515841419870366.
View
19.
Yoon K, Im S, Seo M
. Changes of tear film and ocular surface in diabetes mellitus. Korean J Ophthalmol. 2005; 18(2):168-74.
DOI: 10.3341/kjo.2004.18.2.168.
View
20.
Manaviat M, Rashidi M, Afkhami-Ardekani M, Shoja M
. Prevalence of dry eye syndrome and diabetic retinopathy in type 2 diabetic patients. BMC Ophthalmol. 2008; 8:10.
PMC: 2435518.
DOI: 10.1186/1471-2415-8-10.
View